ROBERT F TODD, MD, PHD
Osteopathic Medicine in Ann Arbor, MI
License number
Michigan 42479
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1500 Floor Cancer & Geriatrics Ctr, Ann Arbor, MI 48109
Phone
(734) 936-6000
(734) 936-2047
(734) 936-2047
Personal information
See more information about ROBERT F TODD at radaris.comName
Address
Phone
5110 Tucker St, Midland, MI 48640
5225 Pine Dr, Jackson, MI 49201
522 Godfroy Ave, Monroe, MI 48162
4624 W Saginaw Rd, Vassar, MI 48768
5795 Otto Rd, Charlotte, MI 48813
Professional information
Robert Franklin Todd, Houston TX
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology, Adult Medicine
Work:
One Baylor Plaza
1 Baylor Plz, Houston, TX 77030 University of Michigan Medical School
1500 E Medical Center Dr, Ann Arbor, MI 48109 Baylor College of Medicine
6620 Main St, Houston, TX 77030
1 Baylor Plz, Houston, TX 77030 University of Michigan Medical School
1500 E Medical Center Dr, Ann Arbor, MI 48109 Baylor College of Medicine
6620 Main St, Houston, TX 77030
Education:
Duke University(1976)
Method Of Reducing Tissue Damage At An Inflammatory Site Using A Monoclonal Antibody
US Patent:
4840793, Jun 20, 1989
Filed:
Jun 11, 1987
Appl. No.:
7/061336
Inventors:
Robert F. Todd - Ann Arbor MI
Benedict R. Lucchesi - Ann Arbor MI
Paul J. Simpson - Ann Arbor MI
James D. Griffin - Sherborn MA
Stuart F. Schlossman - Newton Centre MA
Benedict R. Lucchesi - Ann Arbor MI
Paul J. Simpson - Ann Arbor MI
James D. Griffin - Sherborn MA
Stuart F. Schlossman - Newton Centre MA
Assignee:
Dana-Farber Cancer Institute - Boston MA
The University of Michigan - Ann Arbor MI
The University of Michigan - Ann Arbor MI
International Classification:
A61K 39395
US Classification:
424 858
Abstract:
A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.
Method Of Reducing Tissue Damage At An Inflammatory Site Using A Monoclonal Antibody
US Patent:
4935234, Jun 19, 1990
Filed:
Mar 7, 1988
Appl. No.:
7/165025
Inventors:
Robert F. Todd - Ann Arbor MI
Paul J. Simpson - Ann Arbor MI
Benedict R. Lucchesi - Ann Arbor MI
James D. Griffin - Sherborn MA
Paul J. Simpson - Ann Arbor MI
Benedict R. Lucchesi - Ann Arbor MI
James D. Griffin - Sherborn MA
Assignee:
Dana-Farber Cancer Institute - Boston MA
International Classification:
A61K 39395, C07K 1528, C12P 2108
US Classification:
424 858
Abstract:
A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.